

Pre-Processing of Metabolomics Data (NMR)

Wednesday, July 24, 2013 (9:15-9:55 am)

SOP for Sample Preparation:

- Urine Samples
- Blood Samples
- Tissue and Cell Extractions

What Will I Need to Run NMR:

- Deuterated Solvents
- External Standards
- NMR Tubes and Rotors

¹H-NMR Acquisitions:

- Water Suppression
- Large Molecule Suppression
- Acquisition Parameters


³¹P/ ¹³C-M multinuclear NMR:

- High Energy Phosphates
- ¹³C-Metabolic Fluxes

Two-Dimensional (2D)-NMR:

- COSY, HSQC
- Metabolic Chemical Shift Libraries

Bibliographic Search in PubMed and Chemical Abstracts Plus



Dettmer, Aronov, Hammock, 2006

Step 1: Sample Collection

- If you have a new study, the recommended study design is

Cell cultures → Animal Tissues → Patient

- All specimens for metabolomics need to be snap frozen!
- Diet, exercise, age, sex, animal strain – artifacts for metabolomics analysis

Step 2: Sample Analysis


NMR-based analysis:

- robust,
- fast,
- minimal sample preparation,
- non-destructive,
- large data base;
- low sensitivity (umol),
- low metabolite resolution,
- only small molecules

NMR-Analysis

- **1H-NMR**: global profile of watersoluble and lipid metabolites (amino acids, neurotransmitters, osmolytes, carbohydrates, lipids, lactate – total up to 35 quantitative end-points)
- **31P-NMR**: (tissues and cells only): high energy phosphates, phospholipids and their precursors, sugar phosphates (total 10-12 quantitative endpoints)
- **13C-NMR**: requires addition (incubation) of a ¹³C-precursor (glucose and fatty acid metabolism, metabolic fluxes, glucose uptake, lactate production)

¹H-NMR of Biological Samples

| | NMR (with cryo probe) | GC-MS | DI-MS |
|------------------|---|--|--|
| Techniques |  |  |   |
| Metabolites | Water-soluble (amino acids, organic acids, sugars) | mainly water-soluble (some hydrophobic) | Mainly hydrophobic (some water-soluble) |
| Types of samples | Biofluids, plant, bacterial, animal tissue extracts, Food | Biofluids, plant, bacterial, animal tissue extracts, Food | Mainly biofluids |
| Sample Volume | 0.1-0.5 mL (min) | 30-50 µL (min) | 10 µL |

¹H-NMR of Biological Samples




| | NMR | GC-MS | DI-MS |
|--------------------------------|-------------------------------|-------------------------------|-----------------------------|
| Sample prep time | 30 -120 min/20 samples | 30 -120 min/20 samples | 3-4 h for 96 samples |
| Run time | 20 -90 min/sample | 30-60 min/sample | 7 min/sample |
| Data Analysis | 30-60 min / sample | 30-60 min / sample | 1-2 h for 96 samples |
| Limit of Detection | ~ 5 µM | ~ 100 nM | ~ 5 nM |
| No. of metabolites | ~ 20 - 50 | ~20 -50 | ~ 100-180 |
| Overlapping Metabolites | 10-15 | 10-15 | 10-15 |
| Cross-checking | 10-30 % | 10-30 % | 10-30 % |

| Biofluid | Required Sample Handling | Disease Application |
|-----------------------------------|---|---|
| Urine | Add deuterated phosphate buffer to 0.5 – 3 mL urine | Drug Toxicity/ Efficacy Inborn Metabolic Error Renal Transplantation Renal/ OBGYN/ GU Cancer? |
| Blood Plasma Serum | For 0.5 mL of heparinized blood product: -only deuterium oxide addition (lock) -acetonitrile addition (protein precipitation) -methanol/chloroform extraction (lipid separation) | Drug Treatment Cancer Transplantation Obesity and Diabetes Cardiovascular Disorders |
| CSF | Addition of deuterium oxide to 0.5 mL CSF | Neurology Psychiatry |
| EPS | Add deuterium oxide to 0.03 – 0.10 mL EPS | Prostatic Cancer |
| Bile | Add deuterated methanol to 0.5 mL bile | Liver Transplantation |
| BALF | Add deuterium oxide to 0.5 mL BALF | Pulmonary Drug Toxicity |
| Tissue | -add 0.01 mL deuterium oxide to 3-10 g tissue in MAS rotor -perchloric acid extraction on 20-200 g frozen tissue -methanol/chloroform extraction on 20-200 g frozen tissue | Cancer Drug Treatment Transplantation Obesity Ischemia/ Reperfusion Others |

¹H-NMR of Processed Blood


ABlood,
Plasma

Blood extract

LipophilicDual-
PhaseHydrophilic D_2O 


¹H-NMR of Body Fluids

Data from NMR Spectroscopy: A Typical Control Rat Urine




¹H-NMR of Body Fluids


Annotated Rat Urine Spectrum




¹H-NMR of Body Fluids




¹H-NMR of Body Fluids





$^1\text{H}/^{31}\text{P}$ -NMR of Tissues/ Cells



^{13}C -NMR of Metabolic Fluxes







NMR Spectra Acquisition

- Chemical shift referencing (TMS, DSS)
 - Calibrates/normalizes chemical shifts
- Shimming
 - Fixes line shape to look Lorentzian
- Phasing
 - Fixes line shape to look “absorptive”
- Water suppression/removal
 - Removes large water signal
- Baseline correction
 - Makes spectrum look flat – not wobbly

NMR Spectra Acquisition




Phase Spectrum




After auto phasing, do manual phasing as necessary

NMR Phasing


The Phase of an NMR Spectrum




Baseline Correction




Baseline Correction – Auto Spline



Two-Dimensional NMR



NMR Spectral DBs



The HMDB Biofluid Database

- Reference metabolite concentrations for >450 different diseases & conditions
- Abnormal and normal metabolite concentrations for >15 biofluids and >4500 different metabolites
- Designed for clinical chemists & physicians
- Largest & most complete resource of its kind

| HMDB ID | Chemical Name (InchiKey) | Patient Status | Age | Sex | Reference |
|--------------------------|--------------------------------------|---|----------|-----------------------|---|
| HMDB003375 [BioCarta] | (S)-Lumene | 0.19 (0.02 - 2.40) after a single oral dose of 200 mg of dihydroxyacetone | normal | Adult > 18 yrs old | Wang S, Chen Y, Gao Z, et al. (2007). Dihydroxyacetone: a new biomarker for the early detection of breast cancer. <i>Cancer Lett.</i> 257: 120-126. doi:10.1016/j.canlet.2007.03.031 |
| HMDB0181 [BioCarta] | (R)-erythroisomeric 2-hydroxyacetone | 202.29(222) μM | normal | Adult > 18 yrs old | Kurt C, Riedel S, Bauer M, et al. (2007). Dihydroxyacetone is a biomarker for the early detection of breast cancer. <i>Annals New York Academy of Sciences</i> 1117: 125-135. doi:10.1196/annals.1372.63007 |
| HMDB003311 [BioCarta] | (R,S)-Hydroxybutyric acid | 1580.0 ± 100.0 | normal | Children 1-13 yrs old | Shah N, Karpur SS, Mukherjee A, et al. (2007). Dihydroxyacetone is a biomarker for the early detection of breast cancer. <i>Cancer Lett.</i> 257: 120-126. doi:10.1016/j.canlet.2007.03.031 |
| HMDB003311 [BioCarta] | (R,S)-Hydroxybutyric acid | 3750.0 ± 300.0 | abnormal | Children 1-13 yrs old | Shah N, Karpur SS, Mukherjee A, et al. (2007). Dihydroxyacetone is a biomarker for the early detection of breast cancer. <i>Cancer Lett.</i> 257: 120-126. doi:10.1016/j.canlet.2007.03.031 |
| HMDB003311 [BioCarta] | (R,S)-Hydroxybutyric acid | 1462.0 ± 100.0 | normal | Adult > 18 yrs old | Shah N, Karpur SS, Mukherjee A, et al. (2007). Dihydroxyacetone is a biomarker for the early detection of breast cancer. <i>Cancer Lett.</i> 257: 120-126. doi:10.1016/j.canlet.2007.03.031 |
| HMDB003311 [BioCarta] | (R,S)-Hydroxybutyric acid | 7750.0 ± 200.0 | abnormal | Adult > 18 yrs old | Shah N, Karpur SS, Mukherjee A, et al. (2007). Dihydroxyacetone is a biomarker for the early detection of breast cancer. <i>Cancer Lett.</i> 257: 120-126. doi:10.1016/j.canlet.2007.03.031 |

David Wishart' Project